US Edition
AI-Driven Medicaid Fraud Exposed; Strength Training Tops Diet Strategies; Why Novo Nordisk Is Suing Hims & Hers – Morning Medical Update
Novo Nordisk alleges Hims & Hers sold unapproved compounded semaglutide, including a copycat oral pill, raising safety and intellectual property concerns amid telehealth compounding growth.
- Yesterday, Novo Nordisk, maker of Ozempic and Wegovy, sued Hims & Hers Health over selling unapproved compounded semaglutide, including a copycat oral pill, which Hims & Hers later removed after legal threats and regulator scrutiny.
- Telehealth compounding firms have grown as patients seeking GLP-1 therapy have turned to compounded alternatives after insurance roadblocks, amid criticism of widespread 'mass compounding' of GLP-1 drugs.
- Novo argued that recent cost reductions make copycat drugs unnecessary, while Hims & Hers marketed compounded semaglutide at about $49 per month introductory and around $99 thereafter.
- Hims & Hers responded that the lawsuit attacks compounded medications and vowed to fight to preserve access, affordability and choice for millions of Americans facing insurance barriers.
- The dispute raises concerns as experts on gray‑market drugs warn compounded GLP-1 products pose safety risks and U.S. regulators may tighten telehealth compounding rules.
12 Articles
12 Articles
Jarvis: Knockoff GLP-1 market is still the Wild West
Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill. It was an audacious attempt for a piece of the lucrative GLP-1 market that came to a swift and disastrous end — the company pulled its product just two days after its launch after U.S. regulators vowed to take “decisive” action against its knockoff drug and others like it.…
Jarvis: The knockoff GLP-1 market is still the Wild West
Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill. It was an audacious attempt for a piece of the lucrative GLP-1 market that came to a swift and disastrous end — the company pulled its product just two days after its launch after U.S. regulators vowed to take “decisive” action against its knockoff drug and others like it.…
Fox Business
The New York LedgerNovo CEO blasts ‘mass compounding’ of GLP-1 drugs as safety battle escalates
GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety."When you go and try to source raw materials from China or unknown sources, put it in an injection, and sell knockoff medication, there is something wrong with this," Mike Doustdar, president and CEO of Novo Nordisk, told FOX Business' Maria Bartiromo.Novo, best known for its blockbuster diabete…
Novo Nordisk Launches Legal War over Weight Loss Drug Wegovy
Danish pharmaceutical giant Novo Nordisk has filed a lawsuit against online telehealth company Hims & Hers, alleging the company has been illegally marketing unapproved copies of its Wegovy obesity treatments in violation of patent protections.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
